To assess the potential of Gluc-LiDps-ZnPP to act as a PDT agent, we selected two breast cancer cell lines: the triple negative MDA-MB-231 cell line, and the HER2 overexpressing SKBR3 cell line. This evidence concerns the gene ERBB2 and breast carcinoma.